Diabetes Mellitus, Type 2, Vascular Diseases
Conditions
Keywords
Diabetes Mellitus, Type 2, Vascular Diseases, Thiazolidinediones, Platelet Aggregation
Brief summary
The purpose of this study is to examine the effects of two diabetes medications, rosiglitazone and pioglitazone, on markers of vascular disease in subjects with type 2 diabetes.
Detailed description
Diabetes is a common disease in the United States, affecting over 10 million Americans. Vascular disease, including heart attack and stroke, affects many diabetic patients and will cause the death of three-fourths of these patients. Because the majority of diabetic patients will suffer complications or death from vascular disease, we will explore treatments that have the potential to reduce or prevent vascular disease in type 2 diabetes patients. Our study will examine the effects of two diabetes medications, rosiglitazone (ROSI) and pioglitazone (PIO), on markers of vascular disease in 20 subjects with type 2 diabetes. It is thought that these two medications will reduce the risk of vascular disease by affecting the platelets and proteins that that regulate the processes involved in clot formation. One-half of the subjects enrolled in our study will take ROSI and the other half will take PIO. We will measure the clumping ability of these subjects' platelets before, during, and after three months of treatment with ROSI or PIO. We will measure the blood concentrations of several proteins (fibrinogen, PAI-1, CRP, adiponectin, and leptin) before and after treatment with the study drugs. These experiments will give us information about any beneficial effects of ROSI and PIO on the clot-forming ability in diabetes patients. We expect that treatment with ROSI and PIO will result in improvement of the disturbed clot-forming processes that predispose diabetic patients to vascular disease.
Interventions
DRUGRosiglitazone
Rosiglitazone 4 mg tablets by mouth daily for 3 months
DRUGPioglitazone
Pioglitazone 30 mg tablet by mouth once daily
Sponsors
University of Arkansas
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Men and women of all races * Age 40-65 years * Diagnosis of type 2 diabetes * hemoglobin A1C ≥ 7% * eligible whether or not currently taking antihyperglycemic medications
Exclusion criteria
* History of rosiglitazone or pioglitazone use in the previous 3 months * Known diagnosis of peripheral vascular disease or cardiac failure * Recent history (within past 6 months) of ischemic stroke, myocardial infarction, percutaneous coronary intervention, or coronary artery bypass surgery * Active liver disease or elevated serum transaminases (ALT \>2.5x upper limit of normal) * Current therapy with oral anticoagulants (warfarin, heparin, low molecular weight heparin), clopidogrel, or immunosuppressive agents * Pregnancy or breastfeeding * Any other condition, in the opinion of the investigator, that renders the subject unable to complete the study, that interferes with optimal participation in the study, or that produces significant risk to the subject
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| determine if treatment with rosiglitazone or pioglitazone affects platelet function as assessed by spontaneous and agonist-induced platelet aggregation | 3 months |
Secondary
| Measure | Time frame |
|---|---|
| adipocytokine concentrations (adiponectin, leptin), hemostatic parameters (fibrinogen, plasminogen activator inhibitor-1), high-sensitivity C-reactive protein | 3 months |
Countries
United States
Outcome results
None listed